PACE-CME

Clinical implications of the evidence from IV iron trials in HF

Clinical implications of the evidence from IV iron trials in HF
RestartResume

10' education - Nov. 15, 2023 - Stefan Anker, MD, PhD, Robert Mentz, MD, and Piotr Ponikowski, MD, PhD

  • Overview

    Stefan Anker, Robert Mentz, and Piotr Ponikowski discuss the evidence from IV iron trials in heart failure, past and present, and what the results mean for clinical practice and patients.

  • Educational information

    This video was distributed by our partner, ReachMD, a leading online learning platform for physicians and other healthcare professionals.

  • Faculty

    • Stefan D. Anker, MD, PhD - Division of Cardiology & Metabolism: Heart Failure, Cachexia and Sarcopenia, Department of Cardiology & BCRT, Berlin, Germany
    • Robert J. Mentz, MD - Associate Professor, Chief, Heart Failure Section, Associate Program Director, Duke Cardiovascular Disease Fellowship, Durham, NC, US
    • Piotr Ponikowski, MD, PhD - Medical University, Centre for Heart Disease, University Hospital in Wroclaw, Poland
  • Disclosures

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of PACE-cme.

  • Funding

    This activity is supported by an independent educational grant from CSL Vifor.

    Click here for the course on ReachMD

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments

Register

We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free